Related Experiment Video
Updated: May 4, 2026
Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
Published on: August 1, 2019
[Effect of flumatinib mesylate on C-MYC, HIF-1α and VEGF in U226 line]
Ming-Xing Chang1, Yan-Ping Ma1
1Department of Hematology, Shanxi Medical University Second Hospital, Taiyuan 030001, Shanxi Province, China.
Abstract:
The objective of this study was to investigate the effect of the new generation of tyrosine kinase inhibitor flumatinib mesylate on C-MYC, HIF-1α and VEGF in multiple myeloma (MM) cell line U266. Different concentrations (1, 5, 10 µmol/L) of flumatinib mesylate were used to act on U266 cell line for 8, 16 and 24 h, and the expression of C-MYC, and HIF-1α genes was detected by real-time fluorescence-quantitative PCR, the expression of C-MYC, HIF-1α and VEGF was measured by Western blot. The results showed that the gene expression of C-MYC and HIF-1 genes decreased gradually with the increasing of flumatinib mesylate concentration (P < 0.05). At the same concentration of flumatinib mesylate, the expression of C-MYC and HIF-1α gene decreased gradually with prolonging of treatment time with the flumatinib mesylate (P < 0.05). When the flumatinib mesylate acted the U266 cell line for 16 h, the expression of C-MYC, HIF-1α and VEGF decreased gradually with the increasing of flumatinib mesylate concentration (P < 0.05). It is concluded that the flumatinib mesylate can reduce the expression of C-MYC, HIF-1 α and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
Insights
Flumatinib mesylate, a tyrosine kinase inhibitor, effectively reduces C-MYC, HIF-1α, and VEGF expression in multiple myeloma cells. This dose- and time-dependent effect suggests its potential as a novel therapeutic agent for multiple myeloma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
- Targeting key molecular pathways, such as those involving C-MYC, HIF-1α, and VEGF, is crucial for effective MM therapy.
- Novel therapeutic agents are continuously being investigated to improve treatment outcomes for MM patients.
Purpose of the Study:
- To investigate the impact of flumatinib mesylate on the expression of C-MYC, HIF-1α, and VEGF in the U266 multiple myeloma cell line.
- To determine the dose- and time-dependent effects of flumatinib mesylate on these molecular targets.
- To evaluate the potential of flumatinib mesylate as a new therapeutic drug for multiple myeloma.
Main Methods:
- U266 multiple myeloma cells were treated with varying concentrations (1, 5, 10 µmol/L) of flumatinib mesylate for different durations (8, 16, 24 hours).
- Gene expression levels of C-MYC and HIF-1α were quantified using real-time fluorescence-quantitative PCR.
- Protein expression levels of C-MYC, HIF-1α, and VEGF were measured using Western blot analysis.
Main Results:
- Flumatinib mesylate treatment led to a significant decrease in C-MYC and HIF-1α gene expression in a dose-dependent manner (P < 0.05).
- Both C-MYC and HIF-1α gene expression levels decreased progressively with increasing treatment duration at consistent flumatinib mesylate concentrations (P < 0.05).
- At 16 hours of treatment, flumatinib mesylate significantly reduced the expression of C-MYC, HIF-1α, and VEGF proteins with increasing concentrations (P < 0.05).
Conclusions:
- Flumatinib mesylate demonstrates a time- and dose-dependent inhibitory effect on C-MYC, HIF-1α, and VEGF expression in the U266 multiple myeloma cell line.
- These findings suggest that flumatinib mesylate holds promise as a potential new therapeutic agent for multiple myeloma.
- Further research is warranted to explore the clinical efficacy and safety of flumatinib mesylate in MM treatment.
